Generate a tailored SOP for Dr. Ryo Morimoto. Improve your application with a focused, well-structured draft.
Ryo Morimoto obtained an M.D. from the Faculty of Medicine at The University of Tokyo in 2011, followed by several years of clinical residency at teaching hospitals. In 2017, he completed his Ph.D. in Biochemistry at the Department of Molecular Biology and Biochemistry, Graduate School of Medicine, University of Tokyo. His doctoral research focused on lipidomics, specifically investigating phospholipids and lipid mediators. After earning his Ph.D., he joined the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, as a post-doctoral fellow. From 2017 to 2024, he investigated the diversification of anticipatory antigen receptors and alternative adaptive immunity in jawless vertebrates (lampreys) while exploring implications for the human adaptive immune system. His work also delved into the evolutionary emergence of lymphopoietic microenvironments and mechanisms of self-tolerance to prevent autoimmunity. In 2022, he advanced to the role of Project Leader and by 2024, Ryo Morimoto established his own independent research team as Group Leader at the Laboratory for Molecular Infection Medicine Sweden (MIMS) at Umeå University.
Laboratory for Molecular Infection Medicine Sweden (MIMS) • Umeå, Sweden
Leading an independent research team focusing on molecular infection medicine.
Max Planck Institute of Immunobiology and Epigenetics • Freiburg, Germany
Investigated antigen receptors and adaptive immunity in jawless vertebrates.
Requirements are standard for Master's programs across Social Sciences and Humanities at Umeå. English 6 proficiency is the general rule.